MarketCap
Facebook
X
Telegram
GBS Revenue | GBS
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue GBS
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4.22 M | 3.05 M | 3.11 M | 1.26 M | 437 K | 1.98 M | - | - | - | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 4.22 M | 437 K | 2.34 M |
Quarterly Revenue GBS
| 2026-Q4 | 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 1.06 M | 897 K | 1.11 M | 897 K | 1.11 M | - | 902 K | 607 K | 872 K | - | 908 K | 917 K | 906 K | - | 457 K | 357 K | - | 357 K | 192 K | 178 K | 373 K | 178 K | 34.3 K | 283 K | 55.4 K | 283 K | -1.53 K | -798 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.11 M | -1.53 K | 539 K |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Medical devices industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Cardiovascular Systems
CSII
|
236 M | - | 0.15 % | $ 844 M |  USA |
 |
ShockWave Medical
SWAV
|
730 M | - | - | $ 12.3 B | USA |
 |
Inari Medical
NARI
|
494 M | - | - | $ 4.23 B | USA |
 |
Abiomed
ABMD
|
1.03 B | - | - | $ 17.2 B | USA |
 |
Allied Healthcare Products
AHPI
|
6.02 M | - | 3.58 % | $ 2.21 M | USA |
 |
Titan Medical
TMDI
|
20.1 M | - | -26.32 % | $ 19.6 M |  Canada |
 |
Natus Medical Incorporated
NTUS
|
473 M | - | 1.94 % | $ 1.05 B | USA |
 |
Axonics Modulation Technologies
AXNX
|
366 M | - | - | $ 3.31 B | USA |
 |
Avinger
AVGR
|
7.65 M | - | -20.74 % | $ 369 K | USA |
 |
ThermoGenesis Holdings
THMO
|
9.44 M | - | -25.84 % | $ 171 K | USA |
 |
Apollo Endosurgery
APEN
|
76.9 M | - | - | $ 475 M | USA |
 |
Talis Biomedical Corporation
TLIS
|
2.13 M | - | 3.55 % | $ 7.96 M | USA |
 |
NuVasive
NUVA
|
1.2 B | - | - | $ 2.07 B | USA |
 |
Viveve Medical
VIVE
|
6.43 M | - | -15.35 % | $ 1.71 M | USA |
 |
SmileDirectClub
SDC
|
471 M | - | -53.45 % | $ 9.71 M | USA |
 |
ViewRay
VRAY
|
102 M | - | 1.54 % | $ 468 M | USA |
 |
CONMED Corporation
CNMD
|
1.37 B | $ 47.96 | -2.48 % | $ 1.49 B | USA |
 |
Acutus Medical
AFIB
|
20.2 M | - | -26.83 % | $ 2.62 M | USA |
 |
ClearPoint Neuro
CLPT
|
37 M | $ 9.05 | -1.04 % | $ 256 M | USA |
 |
BIOLASE
BIOL
|
49.2 M | - | -13.19 % | $ 166 K | USA |
 |
Vapotherm
VAPO
|
68.7 M | - | 6.72 % | $ 34 M | USA |
 |
Delcath Systems
DCTH
|
85.2 M | $ 14.66 | 1.66 % | $ 525 M | USA |
 |
SeaSpine Holdings Corporation
SPNE
|
191 M | - | 0.28 % | $ 270 M | USA |
 |
Zynex
ZYXI
|
192 M | - | - | $ 21.1 M | USA |
 |
Conformis
CFMS
|
62 M | - | - | $ 16.4 M | USA |
 |
Medigus Ltd.
MDGS
|
29.9 M | - | 10.28 % | $ 55.5 M |  Israel |
 |
Cutera
CUTR
|
49.5 M | - | -10.19 % | $ 1.99 M | USA |
 |
Globus Medical
GMED
|
2.94 B | $ 81.12 | -0.36 % | $ 11 B | USA |
 |
Nemaura Medical
NMRD
|
77 K | - | -17.8 % | $ 2.74 M |  Britain |
 |
Neovasc
NVCN
|
2.55 M | - | - | $ 111 M | Canada |
 |
Invacare Corporation
IVC
|
181 M | - | - | $ 24.7 M | USA |
 |
Integra LifeSciences Holdings Corporation
IART
|
1.64 B | $ 12.07 | 1.34 % | $ 925 M | USA |
 |
InMode Ltd.
INMD
|
370 M | $ 13.77 | -1.43 % | $ 890 M | Israel |
 |
Apyx Medical Corporation
APYX
|
52.8 M | $ 2.41 | 1.69 % | $ 99 M | USA |
 |
Accuray Incorporated
ARAY
|
402 M | $ 0.12 | -4.69 % | $ 14.7 M | USA |
 |
IRadimed Corporation
IRMD
|
83.8 M | $ 85.76 | -0.12 % | $ 1.09 B | USA |
 |
Integer Holdings Corporation
ITGR
|
1.85 B | $ 126.54 | -0.01 % | $ 4.4 B | USA |
 |
Inogen
INGN
|
349 M | $ 7.05 | -0.77 % | $ 188 M | USA |
 |
Bruker Corporation
BRKR
|
3.44 B | $ 57.98 | 0.68 % | $ 8.8 B | USA |
 |
Boston Scientific Corporation
BSX
|
20.1 B | $ 45.24 | -0.91 % | $ 67 B | USA |
 |
LivaNova PLC
LIVN
|
1.39 B | $ 79.76 | -1.41 % | $ 4.35 B | Britain |
 |
Pulmonx Corporation
LUNG
|
90.5 M | $ 1.96 | 7.1 % | $ 79.7 M | USA |
 |
Medtronic PLC
MDT
|
36.4 B | $ 94.3 | -1.14 % | $ 121 B | USA |
 |
Cytosorbents Corporation
CTSO
|
37.1 M | $ 4.26 | -19.26 % | $ 265 M | USA |
 |
Myomo
MYO
|
40.9 M | $ 1.2 | -1.64 % | $ 50.2 M | USA |
 |
Nano-X Imaging Ltd.
NNOX
|
13 M | $ 0.35 | -4.75 % | $ 22.7 M | Israel |
 |
InspireMD
NSPR
|
8.98 M | $ 0.47 | 3.69 % | $ 30.2 M | Israel |
 |
Outset Medical
OM
|
119 M | $ 4.07 | -0.85 % | $ 61.9 K | USA |
 |
GenMark Diagnostics, Inc.
GNMK
|
172 M | - | - | $ 1.77 B | USA |
 |
PAVmed
PAVM
|
71 K | $ 2.26 | 4.15 % | $ 1.52 M | USA |